CSPC Pharmaceutical Group (HKG:1093) subsidiary's investigational drug, SYS6010, has been granted breakthrough therapy designation by China's National Medical Products Administration (NMPA), according to a Hong Kong bourse filing on Thursday.
The designation is for SYS6010's use as a monotherapy in treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, after other treatment options have failed.
Lung cancer has a high incidence and mortality rate, with poor prognosis after standard treatments. The designation will enhance regulatory communication and speed up development, as current clinical data shows SYS6010 outperforms standard treatments, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。